Luneri

Vitamin C clinical brief

Vitamin C

Dossier live

Compound

CompoundDossier-backed

Publication state

Dossier live

Published from structured dossier data. Authored scoring and decision-tool promotion can be layered in later.

What it is for

General vitamin C adequacy and tissue store repletion

The clearest current human use case based on dose, outcomes, and clinical coverage.

What moves

Highest-signal biomarkers

Human linked

HbA1c

Glycemic control

Decrease

Grade A

HOMA-IR

Glycemic control

Contested

Grade A

Fasting glucose

Glycemic control

Decrease

Grade B

Research signal

Top caution

Drug interaction

In the HATS trial, antioxidant combination (vitamin C 1000 mg + vitamin E 800 IU + beta-carotene + selenium) blunted the HDL2 benefit of simvastatin-niacin therapy.

Dossier status

Dossier live

Published from dossier data; authored scoring and decision-tool promotion can be layered in later.

Meta-analyses

279

Pooled human evidence

RCTs

400

Randomized clinical trials

Tracked studies

925

Studies currently mapped to this dossier

Clinical memoDossier-backed

Executive summary

Immediate brief

Vitamin C is a compound with its clearest current use in General vitamin C adequacy and tissue store repletion.

This live dossier is anchored by 925 tracked studies, 279 meta-analyses, 400 RCTs and the clearest tracked movement in HbA1c, HOMA-IR, Fasting glucose.

Vitamin C has an excellent safety profile at dietary and standard supplemental doses (<=500 mg/day). In the HATS trial, antioxidant combination (vitamin C 1000 mg + vitamin E 800 IU + beta-carotene + selenium) blunted the HDL2 benefit of simvastatin-niacin therapy.

Anchor decision

General vitamin C adequacy and tissue store repletion

Best current human use case

Publication

Dossier live

Published from structured dossier data; authored scoring and decision-tool promotion can be layered in later.

How to use this brief

1. Orient

Use the overview tab to understand mechanism, safety, scope, and where the current evidence still has blind spots.

2. Pressure-test

Move into evidence and biomarkers once the memo already makes sense, so the tables confirm or challenge the narrative rather than replace it.

3. Operationalize

Finish with dosing and PGx when the compound still looks useful and you are deciding whether it belongs in a real protocol.

Vitamin CDossier livePrimary useGeneral vitamin C adequacy and tissue store repletion

CautionDrug interaction

Major warning

Pregnancy (high-dose supplementation)

Overview

Clinical posture

Start with mechanism and safety, then move into scope, synergies, and the open questions that still matter before going deeper into tables.

Primary signal

Mechanism summary

Read this as the shortest defensible explanation for why the compound belongs in the conversation at all.

Direct ROS scavenging - ascorbate donates electrons to neutralize superoxide, hydroxyl radicals, and peroxynitrite; oxidized to dehydroascorbic acid (DHA), which is recycled back to ascorbate via glutathione-dependent reductase, coupling vitamin C status to cellular glutathione pool

Vitamin E (alpha-tocopherol) recycling - ascorbate reduces tocopheroxyl radical to alpha-tocopherol at the lipid-aqueous interface, sustaining lipid-phase antioxidant capacity and suppressing LDL oxidation and membrane lipid peroxidation; links plasma ascorbate status to oxLDL and MDA levels

NF-kB pathway attenuation - ascorbate reduces IKKbeta activity and blunts IkBalpha phosphorylation, limiting nuclear translocation of NF-kB p65/p50 subunits; reduces transcription of IL-6, TNF-alpha, IL-1beta, MCP-1, and COX-2; effect most pronounced under pro-oxidant inflammatory stimulus

eNOS coupling preservation via BH4 regeneration - ascorbate reduces BH3 radical back to tetrahydrobiopterin (BH4), preventing eNOS uncoupling; maintains NO production over superoxide generation in the endothelium; primary mechanistic explanation for blood pressure-lowering and endothelial function effects observed in clinical MAs

Co-primary

Safety summary

These are the reasons this compound can still break trust if the protocol fit is otherwise attractive.

Vitamin C has an excellent safety profile at dietary and standard supplemental doses (<=500 mg/day).

In the HATS trial, antioxidant combination (vitamin C 1000 mg + vitamin E 800 IU + beta-carotene + selenium) blunted the HDL2 benefit of simvastatin-niacin therapy.

Supporting context

Evidence scope

Read these caveats before assuming the effect sizes generalize cleanly across every population or use case.

Generalizability

Review

A disproportionate share of glycemic and inflammatory RCTs derive from Iran, India, and Pakistan.

Evidence scope

Review

Vitamin C effects on inflammatory markers (CRP, IL-6, TNF-alpha), lipids, and glycemia are strongly modulated by baseline status.

Evidence scope

Review

Oral doses >2g/day increase urinary oxalate and pose clinically relevant risk of calcium oxalate nephrolithiasis in susceptible individuals.

Evidence scope

Review

Virtually all vitamin C supplementation RCTs are short-term (median 8 weeks in the blood pressure MA; <=12 weeks for most metabolic endpoints).

Synergies

Potential pairing logic is useful only when it adds a cleaner decision path, not when it becomes an excuse to stack indiscriminately.

No validated pairing data yet

Declared

No dossier-backed pairing evidence is currently mapped for Vitamin C.

Research unknowns

These are the open questions that still keep the compound from reading like a closed case.

What is the relative contribution of TET-mediated epigenetic demethylation vs. classical antioxidant activity to vitamin C's clinical effects in hematological malignancies and clonal hematopoiesis?

Does vitamin C's pro-oxidant mechanism at pharmacological IV concentrations have clinical utility outside pancreatic cancer, and what patient selection biomarkers predict tumor H₂O₂ sensitivity?

Does vitamin C supplementation provide cardiovascular benefit in East Asian populations, given that most BP and lipid RCTs are from South Asian/Middle Eastern cohorts with lower baseline ascorbate status?

What is the effect of vitamin C supplementation on glycemic control in pre-diabetic (impaired fasting glucose / impaired glucose tolerance) populations specifically, as distinct from established T2DM?